logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Other Chronic Obstructive Pulmonary Disease

    Medications for Other Chronic Obstructive Pulmonary Disease

    FiltersReset Filters
    10 results

    • anoro ellipta

      (umeclidinium bromide and vilanterol trifenatate)
      GlaxoSmithKline LLC
      Usage: ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

    • arformoterol tartrate

      (Arformoterol tartrate)
      Alembic Pharmaceuticals Inc.
      Usage: Arformoterol tartrate inhalation solution is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, via nebulization. It is not intended for acute COPD exacerbations or for treating asthma.

    • arformoterol tartrate

      (arformoterol tartrate)
      Lifestar Pharma LLC
      Usage: Arformoterol tartrate inhalation solution is indicated for the long-term, twice daily maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD exacerbations or for the treatment of asthma.

    • arformoterol tartrate

      (arformoterol tartrate)
      NorthStar RxLLC
      Usage: Arformoterol tartrate inhalation solution is indicated for long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, administered via nebulization. It is not intended for acute COPD exacerbations or for asthma treatment.

    • bevespi aerosphere

      (Glycopyrrolate and formoterol fumarate)
      AstraZeneca Pharmaceuticals LP
      Usage: BEVESPI AEROSPHERE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for acute bronchospasm relief or asthma treatment.

    • combivent respimat

      (ipratropium bromide and albuterol)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: COMBIVENT RESPIMAT is indicated for patients with chronic obstructive pulmonary disease (COPD) who have ongoing bronchospasm and require an additional bronchodilator while using a regular aerosol bronchodilator. It combines ipratropium bromide and albuterol sulfate for enhanced respiratory relief.

    • dupixent

      (Dupilumab)
      sanofi-aventis U.S. LLC
      Usage: DUPIXENT is indicated for treating moderate-to-severe atopic dermatitis in patients 6 months and older, asthma in patients 6 years and older, chronic rhinosinusitis with nasal polyps in patients 12 and older, eosinophilic esophagitis, prurigo nodularis, inadequate COPD management, chronic spontaneous urticaria over 12, and bullous pemphigoid in adults.

    • formoterol fumarate

      (Formoterol Fumarate)
      Alembic Pharmaceuticals Inc.
      Usage: Formoterol fumarate inhalation solution is indicated for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is not intended for acute COPD exacerbations or for the treatment of asthma.

    • incruse ellipta

      (umeclidinium)
      GlaxoSmithKline LLC
      Usage: INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

    • ohtuvayre

      (ensifentrine)
      Verona Pharma, Inc.
      Usage: OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.